Navigation Links
Patheon to Showcase Controlled Release Capabilities at CRS 2013
Date:7/15/2013

(PRWEB) July 15, 2013

Patheon Inc., a leading provider of contract development and manufacturing services to the global pharmaceutical industry, announced today that the company will showcase its controlled release capabilities and softgel technologies at the 40th Annual Meeting & Exposition of the Controlled Release Society (CRS) in Honolulu, Hawaii on July 21 – 24, 2013.

Controlled release technologies often present complex challenges in both development and manufacturing. The scientists at Patheon have years of experience in both of these fields and offer a variety of services and resources to move products from early development to market, while maintaining a longstanding commitment to quality and safety. Patheon offers controlled-release technologies in a multitude of dose forms, including tablets and softgels, to allow customers to cater to their target market and to expand the possible applications of a drug.

Two poster presentations will be given by Abhijit Gokhale, Ph.D., Senior Scientist, Formulation and Process Development, Patheon Inc., on Monday, July 22 and Tuesday, July 23. The presentations will cover extrusion spheronization technique for controlled release of pharmaceutical drugs and formulation development of poorly stable and poorly permeable drugs. Visit http://www.patheon.com for more information.

Patheon representatives will also be available to meet at the CRS conference from July 21 – July 24, 2013 at booth #207, showcasing several of Patheon’s key service offerings. To schedule a meeting in advance send an email to events(at)patheon(dot)com.

Furthermore, Patheon has also recently been published in Drug Development & Delivery’s June 2013 issue; Controlled Release Innovations. Dr. Abhijit Gokhale and Prabal Sundararajan discuss orally disintegrating tablets in their article entitled “Novel Controlled Release Formulation for Orally Disintegrating Tablets Using Ion Exchange Resins.” This publication is just one of many among a library of thought leadership concerning controlled release technologies at Patheon. Visit our Knowledge Library to learn more.

About Patheon

Patheon Inc. (TSX: PTI) is a leading provider of contract development and commercial manufacturing services to the global pharmaceutical industry for a full array of solid and sterile dosage forms. Through the company’s recent acquisition of Banner Pharmacaps – a market leader in soft gelatin capsule technology – Patheon now also includes a proprietary products and technology business.

Patheon provides the highest quality products and services to approximately 300 of the world's leading pharmaceutical and biotechnology companies. The company's integrated network consists of 17 locations, including 13 commercial contract manufacturing facilities and 8 development centers across North America and Europe. Patheon enables customer products to be launched with confidence anywhere in the world. For more information visit http://www.patheon.com.

Read the full story at http://www.prweb.com/releases/2013/7/prweb10924628.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Patheon-Sponsored Event to Highlight “Product Enhancement Through Complex Dosage Forms: Adding Value to Products’ Lifecycle Management”
2. Patheon to Host Complimentary Seminar on “Formulation, Funding and First-in-Man: A Stepwise Guide to Clinical Success”
3. Patheon to Host Webinar on “Accelerating the Drug Development Trajectory by Improving Solubility of New Compounds”
4. Patheon to Present on “Cleaning Validation: Science, Risk and Novel Approaches to Testing”
5. Patheon to Feature its Complex Formulation Technologies Expertise at the Upcoming CPhI – P-MEC –ICSE – BioPh – Pharmatec – Medtec Japan – Conference
6. Patheon to Showcase High Potency Capabilities at Upcoming Tradeshows
7. Patheon Exhibits and Presents at the 2013 IQPC Global Formulation and Drug Delivery Summit
8. Patheon to Present New Updates in Drug Formulation and Bioavailability
9. Patheon to Present at 2013 DCAT Week
10. Patheon Exhibits at the 2013 Biopharmaceutical Development and Production Week
11. Patheon to Present at Informex USA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/21/2017)... , ... (PRWEB) September 21, 2017 , ... ... international scientific and technical congress to review the latest knowledge on these products, ... prestigious international speakers will discuss the impact of Biostimulants on Plant Nutrition, Abiotic ...
(Date:9/21/2017)... , ... September 21, 2017 , ... Lajollacooks4u welcomed the ... The organization, a worldwide society of professional women with high achievement in the ... its annual dinner. , Twelve members began with an olive oil tasting ...
(Date:9/20/2017)... Bell, PA and College Station, TX (PRWEB) , ... ... ... IPS-Integrated Project Services, LLC (IPS), a leading global provider of ... Manufacturing, Inc. the leading provider of prefabricated cleanrooms, today announced the unveiling ...
(Date:9/20/2017)... ... September 20, 2017 , ... RoviSys, a leading independent provider ... opening of an office in Taipei, Taiwan. This new location allows RoviSys to ... new relationships in the region. Located in the Neihu area of Taipei, the ...
Breaking Biology Technology:
(Date:4/11/2017)... PALM BEACH GARDENS, Fla. , April 11, ... biometric identity management and secure authentication solutions, today ... million contract by Intelligence Advanced Research Projects Activity ... technologies for IARPA,s Thor program. "Innovation ... the onset and IARPA,s Thor program will allow ...
(Date:4/6/2017)... -- Forecasts by Product Type (EAC), Biometrics, ... (Transportation & Logistics, Government & Public Sector, Utilities / ... Facility, Nuclear Power), Industrial, Retail, Business Organisation (BFSI), Hospitality ... looking for a definitive report on the $27.9bn Access ... ...
(Date:4/4/2017)... NEW YORK , April 4, 2017   ... solutions, today announced that the United States Patent and ... The patent broadly covers the linking of an iris ... the same transaction) and represents the company,s 45 th ... our latest patent is very timely given the multi-modal ...
Breaking Biology News(10 mins):